InterMune Announces Start Of 14-Day Triple Combination Study Of ITMN-191 In Patients With Chronic Hepatitis C
InterMune, Inc. (Nasdaq: ITMN) announced that it has begun dosing in its Phase 1b clinical trial evaluating ITMN-191, designated R7227 at Roche (SWX: ROG), in combination with Pegasys(R) (pegylated interferon alpha-2a) and Copegus(R) (ribavirin) in treatment-naive patients infected with chronic hepatitis C virus (HCV) genotype 1 infection.
Diabetic Patients With Advanced Hepatitis C Have Double The Risk Of Liver Cancer
Patients who have chronic hepatitis C with advanced fibrosis have twice the risk of developing liver cancer if they also have diabetes. These findings are published in the June issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).
Improving Liver Surgery - University Of Florida
A new study reveals patients with liver cancer who have no other treatment options might benefit from more aggressive operations once considered too risky, report University of Florida scientists, who also published research this month yielding insight into ways to protect the liver during surgery.
USC Study Shows Belly Fat May Affect Liver Function
A study by the University of Southern California (USC) suggests the release of lipids from abdominal fat, which drains directly to the liver, increases overnight, providing additional insight as to how abdominal fat is associated with type 2 diabetes risk.
Sinovac Receives RMB 20 Million Purchase Order For Healive From China's Ministry Of Health To Vaccinate Earthquake Victims
Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, announced that the Ministry of Health has purchased approximately RMB 20 million (US$2.86 million) of the Company's inactivated hepatitis A vaccine, Healive(R), to vaccinate people living in the disaster zone following the May 12th earthquake.
Risk Factors Determined For Infection After Liver Transplantation
Nearly 9 percent of patients who recently underwent liver transplantation suffered a subsequent surgical site infection (SSI). Risk factors included having had biliary-enteric anastomosis (choledocho-jejunal or hepatic-jejunal reconstruction), previous liver or kidney transplant, and more than four red blood cell units transfused.
New Study Finds Gap In Survival Rates For Blacks, Whites With Liver Transplants Has Diminished
A gap in survival rates between whites and minorities who had received a liver transplant appears to have been eliminated, possibly due to the introduction of a new medication to prevent organ rejection, new research finds, Reuters reports. Johnny Hong of the University of California-Los Angeles.
Romark Laboratories Completes Enrollment In U.S. Phase II Study Of Nitazoxanide For Chronic Hepatitis C Genotype 1 Non-Responders
Romark Laboratories, L.C., a privately-owned biopharmaceutical company, announced the completion of enrollment into its Phase II clinical trial to evaluate the safety and efficacy of nitazoxanide in combination with standard of care therapy in U.S.
Hepatitis C Resource Centre England Urges The UK Parliament To Aggressively Tackle The Spread Of Hepatitis C In England
With the launch of the Hepatitis C Action Plan for Scotland Phase II, the Scottish Government has promised over ^Alb43 million to help tackle the spread of this virus. The plan will help to significantly improve testing, treatment, care and support services for Hepatitis C across Scotland.
First USA Use Of New Liver Cancer Technology At Saint Raphael
Scott Helton, M.D., chief of surgery at the Hospital of Saint Raphael, New Haven, Connecticut, an internationally recognized liver surgeon, became the first in the USA to use the new Acculis microwave cancer-fighting technology to destroy liver tumours.